



TARGET AUDIENCE	All staff involved in clinical care of patients within NHS Lanarkshire,
	including acute sector and long-term patients in primary care.
PATIENT GROUP	All adult patients within NHS Lanarkshire.

# **Clinical Guidelines Summary**

#### Assessment

Patient has 1 or more of the following	Patient has 2 or more of the following
BMI less than 16 kg/m2	BMI less than 18.5 kg/m2
Unintentional weight loss greater than 15%	Unintentional weight loss greater than 10%
within the last 3 to 6 months	within the last 3 to 6 months
Little or no nutritional intake for more than 10	Little or no nutritional intake for more than 5
days	days
Low levels of potassium, phosphate or	A history of alcohol abuse or drugs including
magnesium before feeding	insulin, chemotherapy, antacids or diuretics



## Management

- High risk patient: start at 10kcal/kg. Aiming to meet full nutritional requirements between days 4-7.
- Extremely high risk patient: start at 5kcal/kg. Recommend ECG monitoring, if possible, in this patient group.
- **Oral/ enteral nutrition**: Prescribe oral thiamine 100mg three times daily and Multivitamin/ trace element supplement for 4 days.
- **TPN**: Prescribe Pabrinex IV once daily for one dose prior to starting feed and for a further 3 days. Multivitamin/ trace element supplement will be added to TPN. See Appendix 3 if prescribing intravenous thiamine during Pabrinex shortage.



#### Monitoring

- Day 1: Baseline sample prior to starting any feeding regime request U&E, LFT, Mg, PO4, Ca, Glucose and FBC using the Nutrition- Refeeding order set bundle via TrakCare. Request CRP for acute phase response.
- Day 2 and 3: Repeat Nutrition- Refeeding order set bundle a significant reduction in phosphate should alert to the possibility of refeeding syndrome.
- Check that electrolyte status is being maintained and observe patient. Check temperature, stool, fluid balance and drug charts regularly. Repeat Refeeding order set bundle until stable and thereafter at least twice weekly.
- Guidance on replacing potassium, phosphate, calcium and magnesium via the NHS Lanarkshire Guidelines Website and App: <u>Electrolyte Disturbance | Right Decisions (scot.nhs.uk)</u>



# Content

Introduction	Page 3
Aim, Purpose and Outcomes	Page 3
Assessment and Management	Page 3
Monitoring	Page 4
Electrolyte Replacement and Monitoring	Page 5
Roles and Responsibilities of Staff	Page 6
References	Page 7
Appendix 1- Governance Information for Guidance document	Page 8
Appendix 2 - Clinical Consequences table	Page 10
Appendix 3 – IV thiamine guidance for use during Pabrinex shortage	Page 11

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



## **Introduction**

Re-feeding syndrome is a description of the fluid and electrolyte shifts from the extracellular to intracellular compartments that take place in malnourished patients undergoing refeeding.

During starvation, insulin concentrations are low as liver stores of glycogen are mobilized. The glycogen is rapidly converted into glucose and gluconeogenesis activated, resulting in protein and lipid breakdown. Free fatty acids and ketones become the major source of energy.

When feeding is recommenced, there is a switch back to carbohydrate-based energy sources which results in insulin release. This stimulates cellular uptake of glucose, phosphate, potassium and water and anabolic protein synthesis. This process results in severe hypophosphataemia often accompanied by hypokalaemia and hypomagnesaemia. This can happen with oral, enteral and parenteral feeding.

#### Criteria for determining people at high risk of developing refeeding problems

Patient has 1 or more of the following	Patient has 2 or more of the following
BMI less than 16 kg/m2	BMI less than 18.5 kg/m2
Unintentional weight loss greater than 15%	Unintentional weight loss greater than 10%
within the last 3 to 6 months	within the last 3 to 6 months
Little or no nutritional intake for more than 10	Little or no nutritional intake for more than 5
days	days
Low levels of potassium, phosphate or	A history of alcohol abuse or drugs including
magnesium before feeding	insulin, chemotherapy, antacids or diuretics

## Aim, Purpose and Outcomes

- To promote awareness of Refeeding Syndrome; its risks, prevention and optimum management of at-risk patients.
- To ensure all patients admitted to an acute site in NHS Lanarkshire are assessed for malnutrition on admission and weekly thereafter to aid identification of at -risk patients.

#### **Assessment and Management**

Recommend electrolytes are checked and corrected, especially potassium (K), magnesium (Mg), phosphate (PO4) and calcium (Ca).

For patients at risk of refeeding syndrome:

• Dietetics will introduce feeding at maximum 50% of nutritional requirements for first 2 days before increasing to full requirements if no biochemical abnormalities.

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



- High risk patients start at maximum 10kcal/kg and an increase in energy provision will be dependent on trends in biochemistry. Aiming to meet full nutritional requirements between days 4-7.
- Extremely high-risk patients consider starting at 5kcal/kg and an increase in energy provision will be dependent on trends in biochemistry. Recommend ECG monitoring, if possible, in this patient group.
- Dietetics will provide detailed plans on how to increase energy provision at their review of patients.

For patients at risk of refeeding syndrome and commencing Parenteral Nutrition, please speak to the ward dietitian and pharmacist for advice regarding the volume and type of TPN to be administered. If out-of-hours, please refer to your local hospital policy for out-of-hours management of TPN.

For high-risk patients starting on oral or enteral nutrition:

 Prescribe oral thiamine 100mg 3 times a day alongside a multivitamin/trace element supplement for first 4 days of feeding. Thiamine may be crushed and mixed with water if to go via enteral feeding tube. This is an off-label use but advice available from NEWT guidelines.

For patients receiving TPN:

- Prescribe one pair of Pabrinex® ampoules intravenously once daily before feeding commences and continue prescription for 3 days in total. Multivitamins and trace elements will be added to TPN daily by pharmacy.

Monitor glucose especially in Diabetic patients

Monitor and adjust fluid balance carefully.

#### Monitoring

- Take a baseline (Day 1) sample prior to starting any feeding regime request **U&E**, **LFT**, **Mg**, **PO4**, **Ca**, **Glucose and FBC** selecting the **Nutrition- Refeeding** order set bundle via TrakCare and requesting **CRP** (to assess acute phase response)
- Commence oral/enteral/ parenteral feeding
- Repeat **Nutrition- Refeeding** order set bundle on Days 2 and 3 a significant reduction in phosphate should alert to the possibility of refeeding syndrome.
- Check that electrolyte status is being maintained and observe patient
- Check temperature, stool, fluid balance and drug charts regularly

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



- Repeat **Nutrition- Refeeding** order set bundle until stable and thereafter at least twice weekly.
- More frequent monitoring will be required in high-risk individuals; those who fail to stabilise biochemically or clinically and those displaying re-feeding.

## **Electrolyte Replacement and Monitoring**

Guidance on replacing potassium, phosphate, calcium and magnesium via the NHS Lanarkshire Guidelines Website and App: <u>Electrolyte Disturbance | Right Decisions (scot.nhs.uk)</u>

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



## Roles and Responsibilities of Staff

#### Medical staff/ non-medical prescribers:

- Identifying patients at risk of re-feeding syndrome with an aim to prevent and manage refeeding syndrome before nutritional support commenced.
- Prescribing thiamine + multivitamin/ trace element supplement/ Pabrinex depending on oral/intravenous access before starting nutritional support in patients at risk of refeeding syndrome.
- Ensuring biochemical monitoring undertaken daily on commencement of feed and supplementation of electrolytes when appropriate.
- Assessing whether oral/enteral/ parenteral nutrition required and liaising with dietetics/ pharmacy team to ensure the prescribed regimen is based on individual patient requirements.

#### **Nursing staff:**

- Ensuring all patients are screened on admission using the Malnutrition Universal Screening Tool (MUST) and reviewed on a weekly basis thereafter.
- Ensuring patients are referred to the Dietetic department if they have a MUST score of 2 or more
- Note also extended role above for nurse prescribers.

### Pharmacy staff:

- Ensuring at risk patients are prescribed oral/intravenous B vitamins prior to commencement of nutritional support.
- Providing advice on electrolyte supplementation.
- Note extended role above for pharmacist independent prescribers.

#### **Dietetic staff**

- Identifying patients at risk of Refeeding Syndrome with an aim to prevent and manage refeeding syndrome before nutritional support commenced.
- Assessing individual patient risk of Refeeding Syndrome and calculating requirements based on individual patient needs.
- Note also extended role above for dietetic prescribers.

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



# References/Evidence

- · Crook M, Swaminathan R. 1996. Disorders of plasma phosphate and indications for its measurement. Ann Clin Biochem 33: 376-396
- · Hearing SD. 2004. Refeeding syndrome is underdiagnosed and undertreated, but treatable. BMJ 328: 908-909
- · Miller DW, Slovis CM. 2000. Hypophosphatemia in the emergency department therapeutics. AmJ Emerg Med 18: 457-461
- Stroud M, Duncan H, Nightingale J. 2003. Guidelines for enteral feeding in adult hospital patients. Gut 52: (Suppl VII): vii1-vii2 x Refeeding Syndrome Version No.3.1 Date: February 2017 Page 13 of 13 NICE 2006. Nutrition support in adults. Oral nutrition support, enteral tube feeding and parenteral nutrition
- · Mehanna HM, Moledina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ 2008; 336:1495-98
- Austin P, Stroud, M. 2007. Prescribing Adult Intravenous Nutrition. Pharmaceutical Press, Chapter 9- Micronutrients, page 141.
- -NICE Guideline 2006: Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition. <u>Nutrition support for adults: oral nutrition support, enteral tube feeding and parenteral nutrition (nice.org.uk)</u>

NHS GGC Medicines Update: Thiamine and Pabrinex in Refeeding Syndrome: <u>Thiamine</u> and <u>Pabrinex in re-feeding syndrome (cloud.microsoft)</u>

NEWT Guidelines. Thiamine monograph. <u>NEWT Guidelines - Drug Monographs - Thiamine</u>. Accessed online 03/07/24

Specialist Pharmacy Service. Prescribing and using thiamine to prevent refeeding syndrome. Last updated 14 May 2024. Accessed online 05 July 2024. Available from: Prescribing and using thiamine to prevent refeeding syndrome – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice

BAPEN, 2024. Guidance on thiamine replacement in patients at risk of Refeeding Syndrome: Accessed online 01 August 2024. Available from: <u>guidance-on-thiamine-replacement-in-refeeding-syndrome.pdf</u> (bapen.org.uk)

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



Version No.

# Refeeding Syndrome

**CHANGE RECORD** 

Date

Lead Author

# Appendix 1

# 1. Governance information for Guidance document

Lead Author(s):	Pamela Miller
Endorsing Body:	ADTC
Version Number:	4
Approval date	December 2024
Review Date:	December 2027
Responsible Person (if different from lead author)	Pamela Miller

CONSULTATION AND DIS	CONSULTATION AND DISTRIBUTION RECORD		
Contributing Author / Authors	Pamela Miller- Clinical Pharmacist Surgery, University Hospital Wishaw Rebecca Ritchie- Lead Clinical Pharmacist for Surgery, University Hospital Wishaw  The guideline review team would like to thank previous contributors: Rebecca Ritchie, Dawn Stewart, Ian Godber, Christine Brown, Grace Davidson and Sarah Connelly for their input to this guideline to date.		
Consultation Process / Stakeholders:	Amna Aslam- Lead Clinical Pharmacist for Surgery- University Hospital Monklands Karen Cashin- Senior Surgical Pharmacist, University Hospital Hairmyres Hannah Weir- Complex Nutrition Dietitian- University Hospital Wishaw Neil Syme- Consultant Clinical Biochemist, University Hospital Monklands Selina Lamont- Consultant Medicine- University Hospital Wishaw		
Distribution			

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027

Change



June 2020	Pamela Miller	Review- nil added	3
October 2024	Pamela Miller	Review- changes to format, content, addition of IV thiamine advice in Pabrinex shortage	4
		- The state of the	

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



# **Appendix 2: Clinical Consequences Table**

Clinical	Body Systems		
Consequences	Candia	Haamatala visal	
Hypophosphataemia	Cardiac	Haematological	
	Altered Myocardial Fund Cardiac Arrhythmia	tion Haemolytic anaemia WBC Dysfunction	
	Congestive Heart Failure		
	Congestive Heart Failure	Haemorrhage	
		Haemormage	
	Hepatic	Respiratory	
	Liver Dysfunction	Acute ventilatory failure	
Hypokalaemia	Cardiac	Neuromuscular	
	Cardiac Arrhythmia	Weakness, Paralysis,	
	Cardiac arrest	Rhabdomyolysis	
		, ,	
	Renal	Gastrointestinal	
	Decreased Urinary	Constipation	
	Concentrating Ability	lleus	
	Polyuria and Polydipsia		
	Decreased GFR		
	Hepatic	Respiratory	
	Exacerbation of hepatic	Respiratory Depression	
	Encephalopathy	respiratory Depression	
Hypomagnesaemia	Cardiac	Neuromuscular	
	Tachycardia	Ataxia, Confusion, Muscle	
	Cardiac Arrhythmia	Tremors, Weakness, Tetany	
	Gastrointestinal		
	Abdominal pain, Anorex	ia.	
	Diarrhoea, Constipation	,	
Altered Glucose	Hyperglycaemia	Dehydration	
Metabolism	Metabolic acidosis	Osmotic diuresis	
	Hypotension	Hyperosmolar hyperglycaemic non-ketotic coma	
Fluid Balance	Cardiac failure	Pre-renal failure	
	Hypotension	Sudden death	
Vitamin Deficiency	Wenicke-Korsakoff sync	Irome	
	Disorientation/ Short term memory loss		
	Nystagmus or other eye movement disorders		

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027



## Appendix 3- Intravenous thiamine use during Pabrinex shortage

Intravenous thiamine for prevention of refeeding syndrome should be reserved for those with intestinal failure where the oral or enteral route is unavailable.

In these patients where Pabrinex would have been prescribed but if Pabrinex stock is unavailable due to medicine shortage, Intravenous thiamine can be prescribed. This medication is unlicensed and patients should be informed using the NHS Lanarkshire's consent procedure.

#### Dose:

Intravenous thiamine 200mg once daily for one dose prior to feeding and for a further 3 doses.

If you are unsure about when to start intravenous thiamine, please speak to your dietitian or ward pharmacist who can advise and ensure an appropriate supply is made.

Lead Author	Pamela Miller	Date approved	December 2024
Version	4	Review Date	December 2027